Novo Nordisk has launched its weight-loss drug Wegovy in China, following approval from local health authorities in June. This move opens up the treatment to over 180 million people living with obesity in China. Wegovy’s launch intensifies competition with Eli Lilly, whose similar weight-loss drug has yet to go on sale in the country. A pack of four Wegovy injections in China will cost 1,400 yuan ($194), significantly lower than its price in the U.S. However, patients will need to pay out-of-pocket since the drug is not covered by China’s national healthcare insurance.
Wegovy, which contains the active ingredient semaglutide, helps control blood sugar, reduces appetite, and promotes feelings of fullness. Research suggests it can help users lose more than 10% of their body weight. Despite its effectiveness, side effects like nausea and vomiting are common, and some patients may regain weight once treatment stops.
The drug’s popularity has surged worldwide, aided by social media buzz and celebrity endorsements, including Elon Musk. Novo Nordisk’s success with Wegovy has helped it become Europe’s most valuable company, with a market value exceeding $440 billion.
Related Topics:
What Diet Pills Burn Belly Fat
What Are the Best Weight Loss Drugs Medicines and Supplements
